Contributions
Abstract: EP1396
Type: ePoster
Abstract Category: Clinical aspects of MS - 8 Clinical assessment tools
Introduction: Accurate quantification of disability in people with MS is becoming increasing relevant. In clinical care the discovery of disease modifying therapies with impact on progressive MS requires accurate serial assessment of disability to assess eligibility and clinical effect1. In research there is an unmet need for reliable clinical measures that would be expected to change over the 2-3 year life span of a progressive MS trial2. Expanded Disability Status Scale (EDSS) has proven to be both insensitive and unreliable to these tasks3. Body-worn sensors offer the potential of a sensitive, objective and reproducible measure of a walking disability.
Aims: We investigated whether data from body worn sensors would be able to distinguish between controls, people with MS with moderate disability (EDSS 2.5-5.0) and people with MS with more advanced disability (5.5-6.5), whether the data was reproducible and whether parameters correlated with current validated measures.
Method: 69 patients with MS and 24 age and gender matched healthy controls participated in the study. Participants completed a 10m Walk, Instrumented Timed-Up-And-Go (iTUG), Instrumented Sway (iSway) and six-minute walk (6MW) on two separate visits.
Results: Sensor measures captured during the 10m Walk, iTUG and 6MW showed significant difference between the three groups (p=< 0.001). Sensor data showed high reliability with excellent reproducibility across most of the walking parameters (ICC>0.75). Many parameters showed significant correlations (varying from strong to moderate) with validated measures. Particularly strong correlations were found between the walking parameters and EDSS.
Conclusion: Body-worn sensors offer a highly reproducible and sensitive way of disability in people with MS. They show potential for implementation into clinical practice as well as clinical trials as a measure of disability progression.
1 Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83: 278-86.
2 Chataway J. Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS--YES. Multiple Sclerosis Journal 2016; : 1352458516671821.
3 Cohen JA, Reingold SC, Polman CH, Wolinsky JS, International Advisory Committee on Clinical Trials in Multiple Sclerosis. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol 2012; 11: 467-76.
Disclosure:
William Hodgkinson: nothing to disclose
Craig Smith: nothing to disclose
Jessie Moorman Dodd: nothing to disclose
Hannah Young: nothing to disclose
Alex Radford: nothing to disclose
Sarah Kelly: nothing to disclose
Julie Kemp: nothing to disclose
Basil Sharrack: nothing to disclose
Jaydip Ray: nothing to disclose
Claudia Mazza: nothing to disclose
Fabio Storm: nothing to disclose
David Paling: nothing to disclose
Abstract: EP1396
Type: ePoster
Abstract Category: Clinical aspects of MS - 8 Clinical assessment tools
Introduction: Accurate quantification of disability in people with MS is becoming increasing relevant. In clinical care the discovery of disease modifying therapies with impact on progressive MS requires accurate serial assessment of disability to assess eligibility and clinical effect1. In research there is an unmet need for reliable clinical measures that would be expected to change over the 2-3 year life span of a progressive MS trial2. Expanded Disability Status Scale (EDSS) has proven to be both insensitive and unreliable to these tasks3. Body-worn sensors offer the potential of a sensitive, objective and reproducible measure of a walking disability.
Aims: We investigated whether data from body worn sensors would be able to distinguish between controls, people with MS with moderate disability (EDSS 2.5-5.0) and people with MS with more advanced disability (5.5-6.5), whether the data was reproducible and whether parameters correlated with current validated measures.
Method: 69 patients with MS and 24 age and gender matched healthy controls participated in the study. Participants completed a 10m Walk, Instrumented Timed-Up-And-Go (iTUG), Instrumented Sway (iSway) and six-minute walk (6MW) on two separate visits.
Results: Sensor measures captured during the 10m Walk, iTUG and 6MW showed significant difference between the three groups (p=< 0.001). Sensor data showed high reliability with excellent reproducibility across most of the walking parameters (ICC>0.75). Many parameters showed significant correlations (varying from strong to moderate) with validated measures. Particularly strong correlations were found between the walking parameters and EDSS.
Conclusion: Body-worn sensors offer a highly reproducible and sensitive way of disability in people with MS. They show potential for implementation into clinical practice as well as clinical trials as a measure of disability progression.
1 Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83: 278-86.
2 Chataway J. Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS--YES. Multiple Sclerosis Journal 2016; : 1352458516671821.
3 Cohen JA, Reingold SC, Polman CH, Wolinsky JS, International Advisory Committee on Clinical Trials in Multiple Sclerosis. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol 2012; 11: 467-76.
Disclosure:
William Hodgkinson: nothing to disclose
Craig Smith: nothing to disclose
Jessie Moorman Dodd: nothing to disclose
Hannah Young: nothing to disclose
Alex Radford: nothing to disclose
Sarah Kelly: nothing to disclose
Julie Kemp: nothing to disclose
Basil Sharrack: nothing to disclose
Jaydip Ray: nothing to disclose
Claudia Mazza: nothing to disclose
Fabio Storm: nothing to disclose
David Paling: nothing to disclose